Trial reportMenopause (New York, N.Y.)2015
Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment.
Trial report in Menopause (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 65 citations in OpenAlex.
- A Randomized Controlled Trial of Ovarian Suppression in Premenopausal Women: No Change in Free-Living Energy Expenditure.Obesity (Silver Spring, Md.) · 2020Trial
- Gonadotropin-releasing hormone agonist in premenopausal women does not alter hypothalamic-pituitary-adrenal axis response to corticotropin-releasing hormone.American journal of physiology. Endocrinology and metabolism · 2018Trial
- Influence of Estradiol Status on Physical Activity in Premenopausal Women.Medicine and science in sports and exercise · 2018Trial
- Regulation of energy expenditure by estradiol in premenopausal women.Journal of applied physiology (Bethesda, Md. : 1985) · 2015Trial
- Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review.Cureus · 2026Review
- Hormone replacement therapy in surgical menopause after gynecological malignancies.Biomolecules & biomedicine · 2025Review
- Association between lifetime endogenous estrogen exposure and body composition metrics in postmenopausal women: findings from the Tehran Lipid and Glucose Study.BMC women's health · 2024Article
- Brown adipose tissue metabolism in women is dependent on ovarian status.American journal of physiology. Endocrinology and metabolism · 2024Article
- Low Levels of Serum Total Vitamin B12 Are Associated with Worse Metabolic Phenotype in a Large Population of Children, Adolescents and Young Adults, from Underweight to Severe Obesity.International journal of molecular sciences · 2023Article
- Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study.Endocrine connections · 2023Article
- Detrimental Changes in Health during Menopause: The Role of Physical Activity.International journal of sports medicine · 2023Review
- Brown Adipose Tissue-A Translational Perspective.Endocrine reviews · 2023Review
- Aromatase Inhibition Eliminates Sexual Receptivity Without Enhancing Weight Gain in Ovariectomized Marmoset Monkeys.Journal of the Endocrine Society · 2022Article
- Nuts and Metabolic Syndrome: Reducing the Burden of Metabolic Syndrome in Menopause.Nutrients · 2022Review
- Body composition and cardiometabolic health across the menopause transition.Obesity (Silver Spring, Md.) · 2022Review
- Roles of estrogens, estrogen-like compounds, and endocrine disruptors in adipocytes.Frontiers in endocrinology · 2022Review
- All around suboptimal health - a joint position paper of the Suboptimal Health Study Consortium and European Association for Predictive, Preventive and Personalised Medicine.The EPMA journal · 2021Article
- Review
- Effects of Estradiol on Immunoglobulin G Glycosylation: Mapping of the Downstream Signaling Mechanism.Frontiers in immunology · 2021Article
- Estrogen-Driven Changes in Immunoglobulin G Fc Glycosylation.Experientia supplementum (2012) · 2021Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectiveSuppression of ovarian hormones in premenopausal women on gonadotropin-releasing hormone agonist (GnRH(AG)) therapy can cause fat mass (FM) gain and fat-free mass (FFM) loss. Whether this is specifically caused by a decline in serum estradiol (E2) is unknown. This study aims to evaluate the effects of GnRH(AG) with placebo (PL) or E2 add-back therapy on FM, FFM, and bone mineral density (BMD). Our exploratory aim was to evaluate the effects of resistance exercise training on body composition during the drug intervention.
methodsSeventy healthy premenopausal women underwent 5 months of GnRH(AG) therapy and were randomized to receive transdermal E2 (GnRH(AG) + E2, n = 35) or PL (GnRH(AG) + PL, n = 35) add-back therapy. As part of our exploratory aim to evaluate whether exercise can minimize the effects of hormone suppression, some women within each drug arm were randomized to undergo a resistance exercise program (GnRH(AG) + E2 + Ex, n = 12; GnRH(AG) + PL + Ex, n = 12).
resultsThe groups did not differ in mean (SD) age (36 [8] and 35 [9] y) or mean (SD) body mass index (both 28 [6] kg/m). FFM declined in response to GnRH(AG) + PL (mean, -0.6 kg; 95% CI, -1.0 to -0.3) but not in response to GnRH(AG) + E2 (mean, 0.3 kg; 95% CI, -0.2 to 0.8) or GnRH(AG) + PL + Ex (mean, 0.1 kg; 95% CI, -0.6 to 0.7). Although FM did not change in either group, visceral fat area increased in response to GnRH(AG) + PL but not in response to GnRH(AG) + E2. GnRH(AG) + PL induced a decrease in BMD at the lumbar spine and proximal femur that was prevented by E2. Preliminary data suggest that exercise may have favorable effects on FM, FFM, and hip BMD.
conclusionsSuppression of ovarian E2 results in loss of bone and FFM and expansion of abdominal adipose depots. Failure of hormone suppression to increase total FM conflicts with previous studies of the effects of GnRH(AG). Further research is necessary to understand the role of estrogen in energy balance regulation and fat distribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.